Replies to post #197 on Opexa Therapeutics, Inc. (OPXA)

[io_io]

Hi, I dont believe there was anything "new" at the ASM.

I would say that, since then, the MS market got larger thanks to Tysabri PML cases plus the FDA rejection of Cladribine.